future earning, page-3

Based on this info from PRR management.......

A maintenance style treatment like CVac™ would be the first
of its type in the market and would initially aim to take 10% of
this ovarian cancer market
• A 10% market share equates to approximately US$360m
• Cvac™ has indications across a multitude of cancers.


http://www.primabiomed.com.au/projects/prodDocuments/PRR%20ASX%20Investor%20Presentation%2021April%2009.pdf


600 million shares on issue
$30 million NPAT
Price Earnings Ratio 20
Earnings per share .05 cents
Share Price $1


750 million shares on issue
$30 million NPAT
Price Earnings Ratio 10
Earnings per share .04
Share Price .40 cents


1 Billion shares on issue
$20 million NPAT
Price Earnings Ratio 20
Earnings per share .02
Share Price .40 cents



Dendreon $2 Billion Market Cap selling Provenge into a $5 Billion Market for prostrate cancer.
$20 share price

Prima Biomed $1.2 Billion Market Cap selling Cvac into a $3 Billion Market for ovarian cancer.
$1.20 (based on 1 Billion shares on issue)


Have Fun :)